Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CART-TM4SF1 + CART-EpCAM
- Development stage
- Unknown
- Lead developer
- Suhaichuan Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CART-TM4SF1 + CART-EpCAM is an investigational combination chimeric antigen receptor (CAR) T-cell therapy being developed by suhaichuan for the treatment of advanced solid tumors. The therapy involves the administration of two distinct CAR-T cell products: one targeting Transmembrane 4 L Six Family Member 1 (TM4SF1) and the other targeting Epithelial Cell Adhesion Molecule (EpCAM). Both antigens are frequently overexpressed in epithelial-derived malignancies such as pancreatic, colorectal, gastric, and lung cancers. To enhance safety, the CAR constructs incorporate an epidermal growth factor receptor (EGFR)-based safety switch, allowing for the selective elimination of the engineered cells if toxicity occurs. It is currently being evaluated in a Phase 1 clinical trial to assess safety, tolerability, and preliminary anti-tumor activity.
- Other names
- TM4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapyTM-4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapyTM 4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapy
02
Targets
EPCAM (Epithelial cell adhesion molecule)TM4SF1 (Transmembrane 4 L6 family member 1)
Beyond the preview
Go deeper on CART-TM4SF1 + CART-EpCAM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CART-TM4SF1 + CART-EpCAM.